These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 20588235)

  • 1. Neuroendocrine evidence of normal hypothalamus-pituitary dopaminergic function in Huntington's disease.
    Markianos M; Panas M; Kalfakis N; Hatzimanolis J; Vassilopoulos D
    Neuro Endocrinol Lett; 2010; 31(3):359-62. PubMed ID: 20588235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma homovanillic acid and prolactin in Huntington's disease.
    Markianos M; Panas M; Kalfakis N; Vassilopoulos D
    Neurochem Res; 2009 May; 34(5):917-22. PubMed ID: 18841471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypothalamic-endocrine aspects in Huntington's disease.
    Petersén A; Björkqvist M
    Eur J Neurosci; 2006 Aug; 24(4):961-7. PubMed ID: 16925587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypothalamic-pituitary-adrenal axis functioning in Huntington's disease mutation carriers compared with mutation-negative first-degree controls.
    van Duijn E; Selis MA; Giltay EJ; Zitman FG; Roos RA; van Pelt H; van der Mast RC
    Brain Res Bull; 2010 Oct; 83(5):232-7. PubMed ID: 20713132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weight loss in Huntington disease increases with higher CAG repeat number.
    Aziz NA; van der Burg JM; Landwehrmeyer GB; Brundin P; Stijnen T; ; Roos RA
    Neurology; 2008 Nov; 71(19):1506-13. PubMed ID: 18981372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autopsy-proven Huntington's disease with 29 trinucleotide repeats.
    Kenney C; Powell S; Jankovic J
    Mov Disord; 2007 Jan; 22(1):127-30. PubMed ID: 17115386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased hypothalamic-pituitary-adrenal axis activity in Huntington's disease.
    Aziz NA; Pijl H; Frölich M; van der Graaf AW; Roelfsema F; Roos RA
    J Clin Endocrinol Metab; 2009 Apr; 94(4):1223-8. PubMed ID: 19174491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypothalamic and neuroendocrine changes in Huntington's disease.
    Hult S; Schultz K; Soylu R; Petersén A
    Curr Drug Targets; 2010 Oct; 11(10):1237-49. PubMed ID: 20594177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth hormone and ghrelin secretion are associated with clinical severity in Huntington's disease.
    Aziz NA; Pijl H; Frölich M; Schröder-van der Elst JP; van der Bent C; Roelfsema F; Roos RA
    Eur J Neurol; 2010 Feb; 17(2):280-8. PubMed ID: 19845749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of the HPG axis on stress response and depressive-like behaviour in a transgenic mouse model of Huntington's disease.
    Du X; Pang TY; Mo C; Renoir T; Wright DJ; Hannan AJ
    Exp Neurol; 2015 Jan; 263():63-71. PubMed ID: 25246229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant cortical synaptic plasticity and dopaminergic dysfunction in a mouse model of Huntington's disease.
    Cummings DM; Milnerwood AJ; Dallérac GM; Waights V; Brown JY; Vatsavayai SC; Hirst MC; Murphy KP
    Hum Mol Genet; 2006 Oct; 15(19):2856-68. PubMed ID: 16905556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of CAG and CCG repeats in Huntingtin gene among HD patients and normal populations of India.
    Pramanik S; Basu P; Gangopadhaya PK; Sinha KK; Jha DK; Sinha S; Das SK; Maity BK; Mukherjee SC; Roychoudhuri S; Majumder PP; Bhattacharyya NP
    Eur J Hum Genet; 2000 Sep; 8(9):678-82. PubMed ID: 10980573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical correlates of mitochondrial function in Huntington's disease muscle.
    Turner C; Cooper JM; Schapira AH
    Mov Disord; 2007 Sep; 22(12):1715-21. PubMed ID: 17557337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 24-Hour Study of the Hypothalamo-Pituitary Axes in Huntington's Disease.
    Kalliolia E; Silajdžić E; Nambron R; Costelloe SJ; Martin NG; Hill NR; Frost C; Watt HC; Hindmarsh P; Björkqvist M; Warner TT
    PLoS One; 2015; 10(10):e0138848. PubMed ID: 26431314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Huntington disease. A review].
    Bonilla E
    Invest Clin; 2000 Jun; 41(2):117-41. PubMed ID: 10961047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length.
    Becher MW; Kotzuk JA; Sharp AH; Davies SW; Bates GP; Price DL; Ross CA
    Neurobiol Dis; 1998 Apr; 4(6):387-97. PubMed ID: 9666478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine enhances motor and neuropathological consequences of polyglutamine expanded huntingtin.
    Cyr M; Sotnikova TD; Gainetdinov RR; Caron MG
    FASEB J; 2006 Dec; 20(14):2541-3. PubMed ID: 17065224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of meiotic variability of the (CAG)n repeat in the Huntington disease gene.
    Lucotte G; Gérard N; Aouizérate A; Loirat F; Hazout S
    Genet Couns; 1997; 8(2):77-81. PubMed ID: 9219003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma testosterone in male patients with Huntington's disease: relations to severity of illness and dementia.
    Markianos M; Panas M; Kalfakis N; Vassilopoulos D
    Ann Neurol; 2005 Apr; 57(4):520-5. PubMed ID: 15786456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of molecular testing in Huntington's disease.
    Wang V; Yeh TP; Chen CM; Yan SH; Soong BW
    Zhonghua Yi Xue Za Zhi (Taipei); 1999 Sep; 62(9):586-90. PubMed ID: 10502848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.